Want to track TGTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 77 days
TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance
Shares of TG Therapeutics had a volatile journey in the last 12 months and have hit resistance levels in the low 20s again. I expect the company to report strong sequential growth of Briumvi, but with less room for significant increases in the full-year guidance after a large increase in May. New patient starts should exceed 1,400 in the second quarter, and we should hear management comments on how they are preparing for the launch of subcutaneous Ocrevus in Q4.
Seekingalpha | 1 year ago
2025 © Marketlog. All Rights Reserved.
